Aradigm raises $24.7 mil. in IPO; proceeds to fund pulmonary drug delivery programs.
ARADIGM NETS $24.7 MIL. IN INITIAL PUBLIC OFFERING of 2.5 mil. shares at $11 per share. The Hayward, Calif.-based company recently completed the offering, with underwriters Cowen & Co. and Invemed Associates fully exercising their options by purchasing an additional 375,000 shares. Aradigm expects that current capital and proceeds from the offering will fund operations through 1997. Cash and cash equivalents of the company were $10.8 mil. as of March 31.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth